Author

Shruti Lal

Senior Scientist, Zai Lab - Cited by 839 - Cancer Biology - Drug-target interactions - Mechanism of action studies

Biography

PhD in Genetics, Genomics and Bioinformatics (Molecular Genetics Track)  Two Master degree in Botany and Computational Biosciences.   2 year Diploma in e-commerce and web designing.
Title
Cited by
Year
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
RA Burkhart, Y Peng, ZA Norris, RM Tholey, VA Talbott, Q Liang, Y Ai, ...Molecular Cancer Research 11 (8), 901-911, 2013201
133
2013
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells
S Lal, RA Burkhart, N Beeharry, V Bhattacharjee, ER Londin, ...Cancer research 74 (4), 1128-1140, 2014201
104
2014
Posttranscriptional upregulation of IDH1 by HuR establishes a powerful survival phenotype in pancreatic cancer cells
M Zarei, S Lal, SJ Parker, A Nevler, A Vaziri-Gohar, K Dukleska, ...Cancer research 77 (16), 4460-4471, 2017201
85
2017
Crawling through time: transition of snails to slugs dating back to the Paleozoic, based on mitochondrial phylogenomics
M Medina, S Lal, Y Vallès, TL Takaoka, BA Dayrat, JL Boore, T GoslinerMarine Genomics 4 (1), 51-59, 2011201
69
2011
Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
SN Chand, M Zarei, MJ Schiewer, AR Kamath, C Romeo, S Lal, ...Cancer research 77 (18), 5011-5025, 2017201
62
2017
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
JD Steffen, RM Tholey, MF Langelier, JL Planck, MJ Schiewer, S Lal, ...Cancer research 74 (1), 31-37, 2014201
60
2014
The role of PENNYWISE and POUND-FOOLISH in the maintenance of the shoot apical meristem in Arabidopsis
N Ung, S Lal, HMS SmithPlant physiology 156 (2), 605-614, 2011201
57
2011
CRISPR knockout of the HuR gene causes a xenograft lethal phenotype
S Lal, EC Cheung, M Zarei, R Preet, SN Chand, NC Mambelli-Lisboa, ...Molecular Cancer Research 15 (6), 696-707, 2017201
43
2017
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial
F McAllister, DM Pineda, M Jimbo, S Lal, RA Burkhart, J Moughan, ...Cancer biology & therapy 15 (6), 688-698, 2014201
41
2014
WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
S Lal, M Zarei, SN Chand, E Dylgjeri, NC Mambelli-Lisboa, MJ Pishvaian, ...Scientific reports 6 (1), 33323, 2016201
35
2016
MUC1 Promoter–Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer
RM Tholey, S Lal, M Jimbo, RA Burkhart, FF Blanco, JA Cozzitorto, ...Molecular Cancer Research 13 (3), 439-448, 2015201
23
2015
Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: native ribonucleoprotein immunoprecipitation (RIP) assays
JA Cozzitorto, M Jimbo, S Chand, F Blanco, S Lal, M Gilbert, JM Winter, ...Nuclear Bodies and Noncoding RNAs: Methods and Protocols, 239-246, 2015201
16
2015
988 Sequence alterations in the WEE1 non-coding region is a facilitator and marker for pancreatic tumorigenesis
S Lal, F Blanco, TP Yeo, CJ Yeo, JR Brody, JM WinterGastrointestinal Endoscopy 79 (5), AB188, 01401
2
2014
Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor
Discovery and characterization of ZL-220, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitorS Lal, BC Sun, Y Chen, T Huang, N Bhola, V Morton, K Chen, S Xia, ...Cancer Research 82 (2_Supplement), 2594-2594, 2022202
1
2022